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Abstract
A single contrast agent that offers whole-body non-invasive imaging along with the superior sensitivity
and spatial resolution of surface-enhanced resonance Raman scattering (SERRS) imaging would allow
both pre-operative mapping and intraoperative imaging and thus be highly desirable. We hypothesized
that labeling our recently reported ultrabright SERRS nanoparticles with a suitable radiotracer would
enable pre-operative identification of regions of interest with whole body imaging that can be rapidly
corroborated with a Raman imaging device or handheld Raman scanner in order to provide high
precision guidance during surgical procedures. Here we present a straightforward new method that
produces radiolabeled SERRS nanoparticles for combined positron emission tomography (PET)-SERRS
tumor imaging without requiring the attachment of molecular chelators. We demonstrate the utility of
these PET-SERRS nanoparticles in several proof-of-concept studies including lymph node (LN) tracking,
intraoperative guidance for LN resection, and cancer imaging after intravenous injection. We anticipate
that the radiolabeling method presented herein can be applied generally to nanoparticle substrates of
various materials by first coating them with a silica shell and then applying the chelator-free protocol.
Key words: Intrinsic radiolabeling, Surface-enhanced resonance Raman scattering, SERS, Positron emission
tomography, in vivo, Imaging.

Introduction
High-precision intraoperative imaging is
necessary to delineate the true extent of tumor
borders and identify the presence of multiple cancer
foci or micrometastases. Failure to remove these
malignant cells is a major reason for local recurrences
and metastatic spread [1]. We previously
demonstrated that the new generations of
surface-enhanced resonance Raman scattering
(SERRS) nanoparticles we have developed enable the
visualization of the exact extent of malignant and
even premalignant lesions after intravenous injection
in many different mouse models, with microscopic

accuracy [2-10]. Unlike conventional fluorescent
imaging agents, SERRS nanoparticles exhibit
exceptionally low limits of detection, resistance to
photobleaching, unambiguous spectral signatures,
and high multiplexing capabilities [2-4]. There is an
increasing intererest in gold nanoparticles as a
platform for cancer marker detection [11]. Our
recently reported surfactant-free synthesis method of
the gold nanoparticle cores should further aid in
developing nontoxic SERRS nanoparticles with the
potential for clinical translation [12, 13]. In contrast to
fluorescence imaging agents [14], the unique
http://www.thno.org
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spectrum of SERRS nanoparticles does not exist in vivo
and its specificity is therefore not affected by
autofluorescence. The SERRS spectra serve as
molecular fingerprints for optical imaging with very
high signal-to-background ratios [7]. After resection
under white-light, we were able to show that residual
cancer can be visualized with SERRS imaging with
tumor deposits as small as 100 µm being detectable,
thereby minimizing the risk that cancer is left behind
during surgery [4, 9, 15]. The increased precision of
imaging the true extent of cancerous spread could
markedly reduce the need for unnecessary resection
of surrounding healthy tissue. It could also enable
surgeries that are presently deemed unfeasible due to
the proximity of adjacent crucial structures such as
nerves or blood vessels, and allow minimally invasive
and robotically assisted surgical approaches in
situations where currently open surgical approaches
are required. Furthermore, SERRS nanoparticles
naturally accumulate in the reticuloendothelial
system (RES), which has enabled advances in the
intraoperative imaging of cancers involving the liver
and lymph nodes [16-18].
Although SERRS imaging has many advantages,
it does not allow for preoperative surgical planning.
Moreover, the high-resolution SERRS imaging
necessary to observe small cancerous deposits limits
the amount of tissue that can be imaged in an
acceptable time frame during surgical procedures.
These challenges can be overcome by the introduction
of a complementary whole-body imaging modality
that enables rapid pre-operative scans to serve as a
roadmap to localize the macroscopic distribution of
the tumors deep within organs. Given the very low
injected dose of SERRS nanoparticles (<100 fmol/g),
the most important consideration in a complimentary
whole-body imaging modality is the limit of
detection. Thus, positron emission tomography (PET),
which has a sensitivity in the range of 10-11 – 10-12 M,
would represent an ideal complementary imaging
modality for SERRS nanoparticles [19].
In vivo imaging of PET-active SERRS
nanoparticles (PET-SERRS NPs) for clinical
applications has not yet been demonstrated. A
previous report of Raman nanoparticle radiolabeling
describes the attachment of 64Cu to silica via a
molecular chelator, but did not demonstrate the
serum stability of the radiolabeled probe [20]. We note
that 64Cu can attach to silica under conditions similar
to those reported by the authors, albeit weakly with
poor serum stability [21]. Thus, competition for
radionuclide binding by the nanoparticle itself
complicates
efforts
to
perform
traditional
molecular-based chelation and requires further
characterization to demonstrate stable radiolabeling.
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The conventional molecular approach to
radionuclide chelation presents several additional
difficulties. First, the coordination chemistry changes
significantly for different radionuclides, such that a
molecule which chelates one species may fail to
chelate many others. Moreover, some isotopes do not
currently have established, reliable molecular
chelators [22]. Secondly, the nanoparticles may not be
stable under the conditions necessary for molecular
chelation of radioisotopes, such as high temperatures
and low or high pH. Even when a molecular chelator
can be incorporated onto a nanoparticle surface,
undesired side effects may occur, such as changes to
the nanoparticle pharmacokinetics. Furthermore, the
molecular chelators can be stripped from the
nanoparticle surface in vivo, such that the imaging
(e.g., positron emission tomography, single-photon
emission tomography, etc.) and biodistribution
studies do not correspond to the true distribution of
the nanoparticles [23, 24]. In principle, these
shortcomings could be overcome by a suitable
chelator-free approach to SERRS nanoparticle
radiolabeling, but to our knowledge no such method
currently exists.
Chelator-free intrinsic radiolabeling has been
demonstrated in various systems, such as iron oxide
and metal nanoparticles. Established approaches to
intrinsic radiolabeling include direct synthesis from
radioactive precursors [25], exploitation of specific
trapping effects [26, 27], heterogeneous cation
exchange
reactions
[28],
and
heat-induced
coordination of radioactive metal cations [29, 30]. We
recently showed that silica nanoparticles (i.e., without
a gold core and free of molecular chelators) can bind
89Zr, 68Ga, 90Y, 111In, 177Lu, and 64Cu with stability
proportional to the oxophilicity of the radiometal ion
[31]. Subsequently, we demonstrated that the addition
of sulfur to silica nanoparticle surfaces allows stable
radiolabeling of softer, more thiophilic radiometal
ions such as 64Cu [21]. Chelator-free radiolabeling has
also been demonstrated with mesoporous silica
nanoparticles by others [32]. Accordingly, we
hypothesized that intrinsic radiolabeling of our
SERRS nanoparticles could be achieved by optimizing
for incorporation of radionuclides into the silica shell.
We identified the short-lived PET tracer 68Ga (t1/2
= 68 min) as the ideal candidate for the radiolabeling
of SERRS nanoprobes, due to i) its oxophilicity, ii) the
fact that it is readily available from commercial
generators, and iii) its relatively low radiation dose to
healthy tissue resulting from its short half-life [31, 33].
The consideration of radiation dose to healthy tissue
is particularly important for nanoparticle imaging
agents because nanoparticle preparations are
sequestered to a significant degree by the RES [34].
http://www.thno.org
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Because of the short circulation time of these
nanoprobes, 68Ga is optimal for imaging at the
relevant pharmacokinetic time points (i.e. out to 3
hours). The 68-minute half-life ensures that 68Ga is
sufficiently decayed over the course of eight hours to
allow SERRS imaging intraoperatively without the
potential issue of exposure to radioactivity. We note,
however, that the ideal radionuclide will vary
depending upon the application, and that
consideration of the half-life, mechanism of decay
(e.g., positron emission necessary for PET), expected
dose to healthy or diseased tissue, and coordination
chemistry is necessary.

Results and Discussion
We first attempted to radiolabel SERRS
nanoparticles with 68Ga by directly applying the
protocol we had established using pure silica
nanoparticles [31]. The SERRS nanoparticles consist of
a gold core of ∼60 nm diameter, which is coated with a
Raman reporter dye and a ∼30 nm thick silica shell [3,
4]. We hypothesized that exposure to 68Ga under the
proper
reaction
conditions
would
generate
intrinsically radiolabeled SERRS nanoparticles with
68Ga distributed throughout the silica shell (Fig. 1, 2).
We performed a purified elution of 68Ga from the
68Ge/68Ga generator with 0.2 N HCl followed by 68Ga
trapping on a cartridge, which was then eluted after
washing using 0.5 M potassium hydroxide (KOH).
This was followed by neutralization with
hydrochloric acid (HCl) or glacial acetic acid to
achieve pH = 7.0-7.5 [35]. In contrast to our previous
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work with pure silica nanoparticles, the silica shell of
SERRS nanoparticles became extremely porous and
even disintegrated entirely for some nanoparticles
upon exposure to the 68Ga solution (Fig. S1).
Consequently, the radiolabeling was unsuccessful.
The decreased stability of the SERRS
nanoparticle silica shell compared to a pure silica
nanoparticle is likely a consequence of their different
synthetic conditions. In order to selectively generate
silica shells around gold nanoparticles, the
homogeneous nucleation of silica must be sufficiently
disfavored such that heterogeneous nucleation and
growth (i.e., shell formation) occurs, but formation of
free silica nanoparticles is minimized. This is achieved
by decreasing the rate of hydrolysis and condensation
of silica precursors, for example by decreasing the
water concentration during synthesis [36]. Decreased
hydrolysis rates lead to more Si-O-Si broken bonds in
the early stages of silica oligomerization and
densification because the ethoxy groups of tetraethyl
orthosilicate (TEOS) are not completely hydrolyzed
[37-39]. Accordingly, homogenous nucleation is slow,
but the gold nanoparticles provide surfaces to
catalyze the condensation and aggregation reactions
at the beginning of silica formation, thus enabling
preferential nucleation (Fig. S2). However, the
incomplete hydrolysis of silica precursors leads to
broken Si-O-Si bonds within the amorphous silica
structure and greater susceptibility to degradation
[38]. Strategies must be developed, therefore, to
render the radiolabeling procedure less harsh.

Figure 1. Chelator-free radiolabeling of SERRS nanoparticles. 68Ga3+ is obtained from a 68Ge/68Ga generator via direct elution with HCl, rather than purified
elution in KOH. The eluent is neutralized by addition of NH4OH with the hypothesized net effect that K+ cations that catalyze silica dissolution are replaced by NH4+
cations that leave the silica shells intact. The 68Ga-labeled PET-SERRS NPs are then easily purified by centrifugation.

http://www.thno.org
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Figure 2. Schematic of a resulting PET-SERRS nanoparticle. The
PET-SERRS nanoparticle is comprised of a gold nanoparticle core, an adsorbed
layer of Raman active molecules (IR-780), and a silica shell with a radionuclide
(68Ga) embedded throughout.

Since the rate of silica dissolution is catalyzed by
the presence of potassium ions, we hypothesized that
a radiolabeling procedure free of potassium would be
less damaging to the silica shells [40]. Rather than
eluting the 68Ga generator followed by 68Ga trapping
on a cartridge and subsequent elution with KOH, we
directly eluted the generator with 0.1 N HCl and
neutralized the eluent with ammonium hydroxide
(NH4OH) (see Methods for details) (Fig. 1). Because
the NH4+ cations are softer and bulkier than K+, we
hypothesized that they would not intercalate into the
silica matrix as well; additionally, the ionic strength of
the 68Ga solution is decreased using this strategy. The
SERRS
nanoparticles
(10
nM
nanoparticle
concentration, 3.52 x 109 g/mol molar mass, 100 μL,
pH = 8.5) were incubated with the 68Ga solution (100
µL, 37 MBq (1.0 mCi), pH = 7.0-7.5) for 45 minutes at
70 °C, then characterized by instant thin layer
chromatography (iTLC), size exclusion (SE) filtration,
transmission electron microscopy (TEM), dynamic
light scattering, and zeta potential analysis.
Radiolabeling was tested at pH = 7.4 as well as pH =
8.5 and compared to a free 68Ga control that contained
no nanoparticles. The radiochemical yield (non-decay
corrected) was 90.92 +/-1.56% and 95.14 +/- 3.43% for
pH = 7.4 and pH = 8.5, respectively, while the molar
activity was 20-100 Ci/µmol of NPs. Radiochemical
yield was calculated as the amount of radioactivity
bound to the NP after purification via centrifugal
pelleting over the total radioactivity (supernatant plus
NP radioactivity). These controls are necessary, as
macroscale gallium solutions at neutral pH may result
in colloid formation; however, radiochemical (i.e. <
nanomolar) concentrations of gallium in buffer
precludes colloid formation [41].
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Comparison of TEM images before and after
radiolabeling revealed that the stability of the silica
shells was greatly improved compared to the prior
radiolabeling procedure which included the presence
of K+ ions (Fig. 3A-B vs. Fig. S1). However, the
porosity of the silica still increased and the shell
thickness decreased by approximately 7 nm according
to dynamic light scattering (Tables S1, S2).
Nonetheless, the intensity of the SERRS spectrum did
not decrease and the 68Ga radioactivity remained
associated with the nanoparticles (Fig. 3C-D, Fig. S3).
Although iTLC suggested a minor degree of 68Ga
detachment after 3 h in 50 % fetal bovine serum (Fig.
3D), the overall stability of the radiolabeling was
sufficient to move forward with in vivo experiments.
We note that successful radiolabeling with 68Ga was
achieved at 25 °C after only 5 minutes of incubation
with SERRS nanoparticles (Fig. S4), but did not
demonstrate
sufficient
lasting
stability
of
radiolabeling so the 70 °C/45 minutes-protocol was
used for the remainder of the experiments.
The PET-SERRS NPs were evaluated in vivo by
lymph node imaging near the periphery of an
orthotopic 4T1 breast cancer tumor. Lymph node
imaging is especially important for the identification
of sentinel lymph nodes, which are routinely excised
and examined by pathology in clinical practice to
determine if lymphatic metastases exist [10]. Because
the location of the primary draining lymphatic vessel
cannot be determined by visual inspection, sentinel
lymph node imaging is performed clinically by
injection of a contrast agent in and around a tumor
[42]. We previously showed that both radiolabeled
silica nanoparticles and SERRS NPs can identify
sentinel lymph nodes separately [31, 43], but the
combined pre- and intra-operative imaging with a
single PET-SERRS imaging agent has not yet been
demonstrated. The PET-SERRS NPs were injected
subcutaneously at the tumor periphery and into the
tumor itself. PET imaging 4 h post-injection revealed
that much of the signal remained concentrated near
the tumor, suggesting that most of the PET-SERRS
nanoparticles had not migrated from the injection site.
Notably, the cervical lymph node can be visualized
using both PET and Cerenkov imaging with strong
contrast at the 4 h time point (Fig. 4A, Fig. S5). As
Cerenkov luminescence (CL) intensity correlates with
the velocity of the charged particle, the high positron
energy of 68Ga (βmax= 1.9 MeV) results in greater CL
compared to radionuclides such as 18F [44, 45].
Although the axillary LN is the sentinel node for
murine breast tissue, the size and location of the
implanted tumor obscures the axillary LN in the small
anatomical dimensions of a mouse. The cervical LN
drains multiple regions, including the upper
http://www.thno.org
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extremities. The accumulation of PET-SERRS
nanoparticles in the cervical LN occurs because one or
more peripheral injection sites falls into its draining
pathway [46, 47]. The cervical LN imaging illustrates
that LN tracking can be achieved in vivo with
PET-SERRS NPs.
Intraoperative imaging of the cervical LN
confirmed the presence of PET-SERRS NPs via Raman
spectroscopy. The characteristic Raman spectrum of
the PET-SERRS nanoparticles is detectable with a
handheld Raman scanner (Figure 4B, C) [6], and
enables near real-time analysis of the presence of
PET-SERRS NPs. Using the handheld scanner, we
identified the presence of the PET-SERRS NP
fingerprint spectrum in the regions that also exhibited
PET contrast, confirming that the PET-SERRS
nanoparticles remained intact after subcutaneous
injection and migration through the lymphatic
channels. The handheld Raman scanner was used to
guide surgical resection of the cervical LN, first by
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locating it in vivo, and then by confirming that all
SERRS-positive
tissue
had
been
removed.
Post-operative SERRS imaging was performed with
the Raman imaging system to corroborate the
handheld scanner results, and indeed showed that the
lymph node had been completely resected (Fig. S6).
Because the PET-SERRS nanoparticles naturally
accumulate in the RES, they should be well suited for
imaging cancers of the liver. In particular, the high
uptake of nanoparticles in healthy RES tissue and
comparatively much lower uptake of nanoparticles in
cancerous tissue has proven sufficient to delineate
tumors in vivo [48, 49]. Because the cancerous regions
should contain fewer PET-SERRS NPs than the
surrounding liver tissue, the presence of cancer is
expected to manifest in filling defects (i.e., regions of
little to no signal, surrounded by regions of high
signal) with both PET and SERRS imaging. A first
proof-of-principle of this concept for non-radiolabeled
SERRS nanoparticles was recently shown [16].

Figure 3. Characterization of PET-SERRS nanoprobes. (A) Transmission electron microscopy image of PET-SERRS nanoparticles before radiolabeling with
68Ga. (B) Transmission electron micrograph of PET-SERRS nanoparticles after radiolabeling with 68Ga at 70 °C for 45 minutes. (C) SERRS spectrum of PET-SERRS
nanoparticles after radiolabeling at 70 °C for 45 minutes. The characteristic profile of IR-780 is unchanged and the intensity has not decreased. (D) Instant thin layer
chromatography results of SERRS nanoparticle radiolabeling compared to free 68Ga. The percentage of 68Ga bound is determined by integrating the signal at the origin
and dividing by the total integrated signal (see methods).

http://www.thno.org
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Figure 4. Lymph node tracking with PET-SERRS nanoparticles. (A) PET-CT image 4 h after the 68Ga-labeled PET-SERRS nanoparticles were injected around
the periphery of an orthotopic 4T1 breast tumor. A lymph node can be clearly visualized away from the injection sites (arrowhead). (B) SERRS spectrum of
PET-SERRS nanoparticles can be tracked in vivo with a handheld Raman scanner. The cervical LN exhibits the characteristic Raman spectrum of the PET-SERRS
nanoparticle, which are not present outside of the LN. Accordingly, a quick handheld scan can be performed to guide location and resection of the LN. (C) After
resection, the handheld scanner can be used to confirm that the SERRS spectrum is only detected in the excised tissue, indicating clean margins in the resection bed.

Figure 5. Pre-operative staging and intraoperative imaging of liver cancer using PET-SERRS nanoparticles. (A) PET-CT image of tumor-bearing mouse reveals
clear filling defects in the liver (arrows) after injection with PET-SERRS nanoparticles. (B) Intraoperative white light image of the liver from the mouse imaged in (A). Some of the
tumors are visible by naked eye due to their large size and differential color. The location of the tumors matches the filling defects of the PET scan. (C) Maximum intensity
projection (MIP) of the PET imaging data, showing healthy liver (high signal) and filling defects corresponding to tumors. (D) SERRS imaging of the liver provides a high-resolution,
intraoperative map of normal liver (high SERRS signal) and location and extent of the tumors (signal voids). The correlation between PET signal and SERRS signal indicates that
the nanoparticles remain intact and active in vivo. (E) Overlay of photograph and SERRS map shows that the filling defects in the SERRS signal correspond to cancer.

http://www.thno.org

Theranostics 2017, Vol. 7, Issue 12
In order to test whether or not the 68Ga would
remain bound to the SERRS NPs in vivo after
intravenous injection, we injected a wild type mouse
with PET-SERRS NPs (150 μL, 10 nM nanoparticles,
500 μCi, 18.5 MBq 68Ga) and followed the distribution
of
PET
signal
on
positron
emission
tomography-computed tomography (PET-CT). After
only 5 minutes, the PET signal was already localized
to the liver according to PET-CT (Fig. S7). This
concentration of PET signal in the liver is consistent
with the observed biodistribution of SERRS
nanoparticles and with the biodistribution of
68Ga-labeled silica nanoparticles [4, 31]. Moreover, this
signal distribution is not consistent with the
biodistribution of free 68Ga (i.e., not bound by a
chelator), which shows high blood and bladder signal
and relatively low RES signal at 1 and 3 hours
post-injection [31]. Thus, the PET-CT results indicate
that the 68Ga remains sufficiently well bound to the
SERRS nanoparticles in vivo.
To evaluate the utility of PET-SERRS NPs for
delineating liver cancers, we injected them into a
mouse that had been genetically engineered to
develop hepatocellular carcinomas (HCC) [16].
PET-SERRS NPs (150 μL, 10 nM nanoparticles, 500
μCi, 18.5 MBq 68Ga) were intravenously injected into
the tail vein and PET and Cerenkov scans were
obtained 3 h post-injection (Fig. 5A, Fig. S8). The PET
signal exhibited several distinct filling defects
throughout the liver, as hypothesized, suggesting the
presence of tumors. We surgically exposed the livers
of the cancer-bearing mouse and performed
high-resolution SERRS scans in a simulated
intraoperative setting. Even without SERRS contrast,
some large tumors with sizes and locations
corresponding to the filling defects on the PET scan
were clearly visible. The SERRS map demonstrated
pronounced filling defects where tumors were
present, and correlated precisely with the
pre-operative PET images (Fig. 5B-E). The
co-registration of PET and SERRS signals in the liver
indicate that the PET-SERRS nanoparticles remain
intact after intravenous injection and circulation. To
ensure that the PET signal corresponded with the
healthy tissue throughout the volume of the liver, we
also performed PET-MRI scans. The filling defects
(i.e., negative contrast) observed via PET matched
abnormal signal caused by the tumors on MRI,
confirming that the PET-SERRS NPs delineate healthy
versus cancerous tissue throughout the liver (Fig.
6A-C).
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Figure 6. PET-MR imaging of liver cancer using PET-SERRS
nanoparticles. A mouse with genetically engineered hepatocellular carcinoma
(HCC) was injected with 400 µCi of 68Ga-labeled PET-SERRS NPs. After 3
hours, micro-PET-MRI was performed, and data analysis and PET-MRI
co-registration were completed using VivoQuantTM software (InviCro LLC,
Boston, USA). Shown are axial sections through the upper abdomen. A) Axial
T1-weighted MR image through the liver, demonstrating a hypointense region
(dashed-line circle), which was later confirmed to represent a HCC on
pathological examination. Arrowhead = gallbladder. B) PET image with a signal
void (arrow) corresponding to the location of the HCC. C) MRI-PET overlay.

Conclusion
The stability of the PET-SERRS NPs reported
herein, and their utility for in vivo imaging justify
further investigation into their use as whole-body,
combined pre- and intra-operative multimodal
contrast agents. The PET-SERRS NPs enable
whole-body imaging as a pre-operative roadmap and
http://www.thno.org
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intraoperative rapid hand-held SERRS scanning or
high-resolution SERRS imaging for precise surgical
guidance. Notably, this method is likely to work with
a variety of other radionuclides, as observed for pure
silica nanoparticles. Most importantly, this work
introduces a general method for chelator-free
radiolabeling of silica-encapsulated materials, thus
opening many new avenues for their use in
biomedical and other fields. Future research efforts
will seek to improve upon the stability of the silica
shells, such that no morphological changes are
observed after radiolabeling. This will improve
confidence that nanoparticle formulations with
surface-bound species like antibodies will maintain
their composition.

Materials and Methods
SERRS nanoparticle synthesis
Gold nanoparticles were synthesized by adding
7.5 mL 1% (w/v) sodium citrate to 1.000 L boiling 0.25
mM HAuCl4. After the nanoparticle dispersion
reaches the red color indicative of a complete reaction,
it is left to cool for 30 minutes, then concentrated by
centrifugation (10 min, 7500 x g, 4°C) and dialyzed
overnight (3.5 kDa MWCO; 5 L 18.2 MΩ.cm). The
dialyzed gold nanoparticles (140 μL; 2.0 nM) were
added to 1 mL absolute ethanol in the presence of 50
μL tetraethoxyorthosilicate (Sigma Aldrich, 99.999%),
20 μL 28% (v/v) ammonium hydroxide (Sigma
Aldrich) and 2 μL IR-780 dissolved in
N,N-dimethylformamide. IR-780 was selected
because of its resonance with the 785nm laser line,
cationic charge, compatibility with silication, and
consistency with our previous studies. After 25
minutes of shaking (375 rpm) at ambient conditions in
a plastic container, the SERRS-NPs were centrifuged,
washed three times with ethanol, and redispersed in
water to yield 5 nM SERRS-Nanoprobes.

SERRS nanoparticle characterization
Nanoparticles were imaged by transmission
electron microscopy (TEM) acquired on carbon grids
(Ted Pella, Inc.) using a JEOL 1200 EX microscope
(Peabody, MA). Dispersion concentrations were
determined by Nanoparticle Tracking Analysis (NTA;
Nanosight, Duxbury, MA). For radiochemical yield
and serum stability studies see supporting
information.

Radiolabeling protocol
68Ga

(t1/2=68 m) was eluted from a 68Ge-68Ga
generator (ANSTO, Australia) as previously
described [35], with 555-740 MBq (15-20 mCi)
radioactivity per elution. 68Ga was eluted with 0.1 N
HCl (1.5 mL), and either immediately used or trapped
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on a filter, washed, and eluted with 0.5 M KOH (0.500
mL). The 68Ga HCl solution was neutralized with 28%
NH4OH (13 uL) while the 68Ga hydroxide solution
was neutralized with concentrated HCl (20-30 µL).
Upon neutralization, 50-100 µL of 37 MBq (0.5-1.0
mCi) 68Ga was immediately added to SERRS
nanoparticle dispersions (10 nM, in 100 μL of 10 mM
buffer, pH = 7.4 or pH=8.5) and incubated at 70 °C on
a thermomixer at 500 rpm for 45 minutes. Purification
was completed by centrifugation at 10,000 rpm for 120
seconds, followed by decanting the supernatant and
redispersing in buffer (e.g, 2-(N-morpholino)
ethanesulfonic acid).

In vivo experiments
All animal experiments were done in accordance
with protocols approved by the Institutional Animal
Care and Use Committee of Memorial Sloan Kettering
Cancer Center and followed National Institutes of
Health guidelines for animal welfare.

Genetically engineered hepatocellular
carcinoma (HCC) mouse model
To generate endogenous HCCs in mice, a sterile
0.9% NaCl solution/plasmid mix was prepared
containing 5 μg of DNA for the pT3 EF1a-Myc
Sleeping-beauty transposon plasmid mixed with
CMV-SB13 Sleeping-beauty transposase plasmid (1:5
ratio) for each injection. A total volume of the plasmid
mix corresponding to 10% of body weight was
injected into the lateral tail vein of eight to ten week
old female FVBN mice (Jackson laboratory, Ben
Arbor, USA) in 5−7 s. The pT3 transposon vector was
a kind gift by Dr. Xin Chen (UCSF). Approximately 7
weeks after injection, numerous tumors were
observed in the livers. Pathological examination
confirmed that the tumors represented poorly
differentiated HCCs.

PET/CT imaging
At predetermined time points (1h, 3h) animals
were anesthetized with isoflurane (Baxter Healthcare,
Deerfield, IL) and oxygen gas mixture (2% for
induction, 1% for maintenance) and scans were then
performed using an Inveon PET/CT scanner (Siemens
Healthcare Global). Whole body PET static scans were
performed recording a minimum of 50 million
coincident events, with durations of 10-30 min. The
energy and coincidence timing windows were
350−750 keV and 6 ns, respectively. The image data
were normalized to correct for non-uniformity of
response of the PET, dead-time count losses, positron
branching ratio, and physical decay to the time of
injection,
but
no
attenuation,
scatter,
or
partial-volume averaging correction was applied.
http://www.thno.org
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Images were analyzed using ASIPro VMTM software
(Concorde Micro-systems). Whole body standard low
magnification CT scans were performed with the
X-ray tube setup at a voltage of 80 keV and current of
500 µA. The CT scan was acquired using 120
rotational steps for a total of 220 degrees yielding and
estimated scan time of 120 s with an exposure of 145
ms per frame.

Cerenkov luminescence imaging
Mice were anesthetized as described previously.
Open filters were used for optical scans. 120-300 s
scans were completed, depending on the photon flux.

Handheld SERRS detection
All handheld Raman measurements were
performed using the MiniRam Raman handheld
scanner (B&W TEK, Inc., Newark, DE) equipped with
a 785 nm laser.[6, 10] Raman spectra were collected
with an acquisition time of 1 s and analyzed with
B&WSpec 4.01.26 Software (B&W TEK).

Fixed-microscope SERRS imaging
All fixed Raman scans were performed using a
Renishaw inVia Raman microscope with a 300mW
785 nm diode laser and 1-inch charge-coupled device
detector (1.07 cm-1 spectral resolution). The SERRS
spectra were collected with a 5× objective (Leica) and
the laser output measured at the objective was 100
mW at 100% laser power. Scans were typically
performed at 100 mW laser power, 1.5-s acquisition
time, using the StreamLine high-speed acquisition
mode. The Raman maps were generated by means of
a DCLS algorithm (WiRE 3.4 software, Renishaw).

PET-MRI
A
mouse
with
genetically
engineered
hepatocellular carcinoma (HCC) was injected with
400 µCi of 68Ga-labeled PET-SERRS NPs. After 3
hours, micro-PET-MRI was performed (T1-weighted)
on a nanoScan PET/MRI system (Mediso USA,
Boston, MA) and the data analysis and PET-MRI
co-registration were completed using VivoQuantTM
software (InviCro LLC, Boston, USA).
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